Regeneron invents, develops and commercialises life transforming medicines for people with serious diseases. Founded and led by physician scientists, the company translates science into medicine through proprietary technologies including VelociSuite and the Regeneron Genetics Center. With 13 approved medicines and 45 candidates in development, Regeneron addresses eye diseases, allergic conditions, cancer, cardiovascular diseases and rare diseases. Operating across 12 countries with trials in over 50 nations, Regeneron employs more than 15,100 colleagues. Guided by doing well by doing good, the company integrates integrity into every operation while advancing health equity, STEM education and environmental sustainability.
15100
Team Members
1988
Founded
Biotechnology
Sector
On-Site
Work Environment
A world where the greatest scientific discoveries continually emerge, transforming into medicines that address humanity's most serious diseases and enabling people to live longer, healthier lives through breakthrough biological research.
Regeneron's mission is to use the power of science to bring new medicines to patients, over and over again.